rs143243059
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4BS1
This summary comes from the ClinGen Evidence Repository: RS1 (NM_000330.4) and an alternative transcript of CDKL5 (NM_003159.2) are overlapping transcripts; however, these variants are in the noncoding 3' region of the main CDKL5 transcript (NM_001323289.2). The allele frequency of the c.2933T>G (p.Leu978Arg) variant in the CDKL5 transcript (NM_003159.2) (RS1 c.185-3213A>C) is 0.01184% in the European (non-Finnish) sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). Computational analysis prediction tools suggest that the p.Leu978Arg variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Leu978Arg variant in CDKL5 is classified as likely benign based on the ACMG/AMP criteria (BS1, BP4). LINK:https://erepo.genome.network/evrepo/ui/classification/CA10360748/MONDO:0100039/016
Frequency
Consequence
NM_003159.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RS1 | NM_000330.4 | c.185-3213A>C | intron_variant | ENST00000379984.4 | NP_000321.1 | |||
CDKL5 | NM_001037343.2 | c.2933T>G | p.Leu978Arg | missense_variant | 21/22 | NP_001032420.1 | ||
CDKL5 | NM_003159.3 | c.2933T>G | p.Leu978Arg | missense_variant | 20/21 | NP_003150.1 | ||
RS1 | XM_047442337.1 | c.-162A>C | 5_prime_UTR_variant | 1/4 | XP_047298293.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RS1 | ENST00000379984.4 | c.185-3213A>C | intron_variant | 1 | NM_000330.4 | ENSP00000369320.3 |
Frequencies
GnomAD3 genomes AF: 0.0000799 AC: 9AN: 112571Hom.: 0 Cov.: 24 AF XY: 0.0000576 AC XY: 2AN XY: 34717
GnomAD3 exomes AF: 0.0000273 AC: 5AN: 183424Hom.: 0 AF XY: 0.0000442 AC XY: 3AN XY: 67852
GnomAD4 exome AF: 0.0000974 AC: 107AN: 1098175Hom.: 0 Cov.: 30 AF XY: 0.0000660 AC XY: 24AN XY: 363531
GnomAD4 genome AF: 0.0000799 AC: 9AN: 112571Hom.: 0 Cov.: 24 AF XY: 0.0000576 AC XY: 2AN XY: 34717
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Sep 29, 2017 | - - |
CDKL5 disorder Benign:1
Likely benign, reviewed by expert panel | curation | ClinGen Rett and Angelman-like Disorders Variant Curation Expert Panel | Feb 20, 2023 | RS1 (NM_000330.4) and an alternative transcript of CDKL5 (NM_003159.2) are overlapping transcripts; however, these variants are in the noncoding 3' region of the main CDKL5 transcript (NM_001323289.2). The allele frequency of the c.2933T>G (p.Leu978Arg) variant in the CDKL5 transcript (NM_003159.2) (RS1 c.185-3213A>C) is 0.01184% in the European (non-Finnish) sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). Computational analysis prediction tools suggest that the p.Leu978Arg variant does not have a deleterious impact; however this information does not predict clinical significance on its own (BP4). In summary, the p.Leu978Arg variant in CDKL5 is classified as likely benign based on the ACMG/AMP criteria (BS1, BP4). - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Oct 30, 2020 | - - |
Developmental and epileptic encephalopathy, 2;CN128785:Angelman syndrome-like Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 14, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at